Evidence mapPaperPMID 41508551Full record

SynthesisObesity reviews : an official journal of the International Association for the Study of Obesity2026

Metabolic Syndrome and Obesity-related cancer Risk and Survival: An Umbrella Review of Systematic Reviews With Meta-analysis of Observational Studies.

Maci Winn, Prasoona Karra, Ryzen Benson, Svenja Pauleck, Nathorn Chaiyakunapruk, Win Khaing, Sajesh K Veettil, Mary M McFarland, Tallie Casucci, Yizhe Xu and 4 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maci WinnDepartment of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0001-7363-0626
Prasoona KarraHuntsman Cancer Institute, Salt Lake City, Utah, USA.ORCID 0009-0008-5209-9846
Ryzen BensonHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Svenja PauleckHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Nathorn ChaiyakunaprukCollege of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
Win KhaingCollege of Pharmacy, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-1636-1807
Sajesh K VeettilDepartment of Pharmacy Practice, International Medical University, Kuala Lumpur, Malaysia.
Mary M McFarlandUniversity of Utah, Spencer S. Eccles Health Sciences Library, Salt Lake City, Utah, USA.ORCID 0000-0002-9062-2393
Tallie CasucciUniversity of Utah, J. Willard Marriott Library, Salt Lake City, Utah, USA.
Yizhe XuUniversity of Utah, Department of Internal Medicine, Division of Epidemiology, Salt Lake City, Utah, USA.ORCID 0000-0002-0773-1709
Siwen Hu-LieskovanHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Michelle LitchmanCollege of Nursing, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0002-8928-5748
Mary PlaydonDepartment of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
Sheetal HardikarDepartment of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.

Funding

Interdisciplinary Training Program in MetabolismT32DK091317 · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2025 to 2025
$472k
Metabolic Obesity Phenotypes and Obesity-related Cancer SurvivalF30CA278348 · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2025 to 2025
$55k
NCI NIH HHS F30 CA278348NCI NIH HHS F99 CA264400NCI NIH HHS K00 CA264400NCI NIH HHS K07 CA222060NCI NIH HHS NCIF30CA278348NCI NIH HHS NCIF99CA264400NCI NIH HHS NCIK00CA2644000NCI NIH HHS NCIK07CA222060NCI NIH HHS NCIR00CA218694NCI NIH HHS R00 CA218694NIDDK NIH HHS T32 DK091317NIDDK NIH HHS T32DK091317
6 · The paper itself

Abstract

introductionMetabolic syndrome (MetS) may be associated with obesity-related cancer (ORC) owing to shared risk factors like physical inactivity, insulin resistance, gut microbiome dysfunction, and inflammation. We conducted an umbrella review of systematic reviews with meta-analysis to synthesize the evidence on the association between MetS and ORC risk and survival.

methodsSearches in five databases (Medline, Embase, CINAHL, Cochrane Library, and Scopus) retrieved 2524 systematic reviews with meta-analyses (SRMAs), which underwent title and abstract screening (2524), full-text review (41), and data extraction for included SRMAs (21). Summary effects and 95% confidence intervals were re-estimated using random-effects models. Methodological quality, certainty of evidence, and publication bias were assessed using the AMSTAR 2, modified Ioannidis criteria, and Egger's test, respectively.

resultsA total of 25 associations between MetS and ORC risk and five between MetS and survival were evaluated. Overall, 10 associations evaluating MetS and ORC risk were highly suggestive (four) or suggestive (six), while the rest were classified as weak (seven) or nonsignificant (eight). One association was suggestive for MetS and ORC survival, while the rest were classified as weak (three) or nonsignificant (one). The Egger's and excess significance tests were significant for 8(32%) associations between MetS and ORC risk and 3(60%) associations between MetS and ORC survival.

conclusionThis umbrella review suggests metabolic syndrome increases the risk of several obesity-related cancers and worsens colorectal cancer survival. Despite study variability, consistent associations across diverse populations highlight the urgency of prevention and management strategies targeting metabolic dysfunction to reduce cancer burden. Summary In this umbrella review, highly suggestive and suggestive evidence supports associations between MetS and the risk and survival of several obesity-related cancers. However, a better understanding of the relationship between metabolic syndrome and obesity-related cancers is still needed to provide appropriate clinical care, design optimal interventions, and prevent subsequent increases in the risks of cancer, morbidity, and mortality.

Indexed as

Metabolic SyndromeNeoplasmsObesityHumansObservational Studies as TopicRisk FactorsSystematic Reviews as Topiccancer riskcancer survivalepidemiologymetabolic syndromeobesity‐related cancersystematic reviewumbrella review

Identifiers

PMID41508551
PMCPMC12795314

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.